PDCD1 and neoplasm: Our approach to focus on preclinical tumor models with similar genetic background but different sensitivity to anti-PD-1 therapy would contribute to understanding mechanism of anti-PD-1 response more clearly and to generating a novel concept to synergize anti-tumor activity of anti-PD-1and to target anti-PD-1 non-responder patients.